({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}carbamoyl)methyl acetate

• ChemBase ID: 6406
• Molecular Formular: C19H28N2O4
• Molecular Mass: 348.43662
• Monoisotopic Mass: 348.20490739
• SMILES: O(c1cc(CN2CCCCC2)ccc1)CCCNC(=O)COC(=O)C
• Canonical SMILES: O=C(COC(=O)C)NCCCOc1cccc(c1)CN1CCCCC1
• InChI: InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)
• InChIKey: SMTZFNFIKUPEJC-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: ({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}carbamoyl)methyl acetate
• IUPAC Traditional name: roxatidine
• Brand Name: Roxit
• Synonyms: Roxatidine; Aceroxatidine; Roxatidina; Roxatidinum; Pifatidine; Roxatidine acetate

Database IDs

• CAS Number: 78628-28-1
• PubChem SID: 160969713
• PubChem CID: 5105

CALCULATED PROPERTIES

JChem

• Acid pKa: 14.8782835
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): -1.7924889
• LogD (pH = 7.4): -0.12762822
• Log P: 1.3130374
• Molar Refractivity: 96.3186 cm^3
• Polarizability: 37.719524 Å^3
• Polar Surface Area: 67.87 Å^2
• Rotatable Bonds: 10
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 2.27
• LOG S: -3.76
• Solubility (Water): 6.12e-02 g/l

DETAILS

DrugBank - DB08806

• Drug Groups: approved
• Description: Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
• Indication: For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers
• Pharmacology: Roxatidine acetate suppresses the effect of histamine on the parietal cells of the stomach (H2-receptor antagonist). This suppressive action is dose-dependent. As a result, the production and secretion, particularly of gastric acid, are reduced. Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver.
• Toxicity: Oral, mouse LD50: 1000 mg/kg
• Affected Organisms: Humans and other mammals
• Biotransformation: Roxatidine acetate is rapidly metabolised to the primary, active desacetyl metabolite.
• Absorption: Well absorbed orally (80–90% bioavailability).
• Half Life: 5-6 hours
• Protein Binding: 5-7%
• References: [Product Insert]
• External Links: Wikipedia

REFERENCES

• Product Insert